For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Regenxbio Inc.

USPTO Granted Patents = 16

EPO Patents = 4

Trademarks = 20

Forward Citations = 9

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Olivier Danos (5 out of 5 patents)

Ye Liu (4 out of 35 patents)

Devin Mcdougald (4 out of 4 patents)

4. Karen Kozarsky (3 out of 10 patents)

5. Franz M Gerner (3 out of 3 patents)

6. Chunping Qiao (3 out of 4 patents)

7. Walter C Low (2 out of 13 patents)

8. R Scott McIvor (2 out of 10 patents)

9. Carolyn Ann Fairbanks (2 out of 8 patents)

10. Li Zhi (2 out of 4 patents)

11. Claire G Zhang (2 out of 2 patents)

12. Lalitha R Belur (2 out of 2 patents)

13. James M Wilson (1 out of 238 patents)

14. Nicholas M Boulis (1 out of 3 patents)

15. Shunji Tomatsu (1 out of 14 patents)

16 patents: Sort by Forward Citations

1. 12766200 - TREATMENT OF DYSTROPHINOPATHIES WITH MICRODYSTROPHIN GENE THERAPY CONSTRUCTS (2026-10-20),

2. 12761144 - Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles (2026-10-13),

3. 12752021 - METHODS OF MANUFACTURING MICRODYSTROPHIN GENE THERAPY CONSTRUCTS (2026-10-06),

4. 12752020 - MICRODYSTROPHIN NUCLEIC ACID GENE THERAPY CONSTRUCTS AND USES THEREOF (2026-10-06),

5. 12697399 - MICRODYSTROPHIN GENE THERAPY CONSTRUCTS AND USES THEREOF (2026-08-04),

6. 12612644 - Scalable method for recombinant AAV production (2026-04-28),

7. 12565645 - METHODS OF SIZE EXCLUSION CHROMATOGRAPHY FOR THE CHARACTERIZATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS COMPOSITIONS (2026-03-03),

8. 12558434 - COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (2026-02-24),

9. 12365865 - Scalable clarification process for recombinant AAV production (2025-07-22),

10. 12247213 - Treatment of mucopolysaccharidosis IVA (2025-03-11),

11. 12121567 - Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase (2024-10-22),

12. 12070702 - Anion exchange chromatography for recombinant AAV production (2024-08-27),

13. 12070510 - Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid (2024-08-27),

14. 11986515 - Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) (2024-05-21),

15. 11613739 - Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells (2023-03-28),

Company Overview

Regenxbio Inc. is a biotechnology company based in Rockville, Maryland, specializing in gene therapy. The organization focuses on developing innovative treatments for various genetic diseases and disorders through its proprietary AAV (adeno-associated virus) technology platform. Regenxbio's research emphasizes the potential of gene delivery systems to provide long-lasting therapeutic effects, aiming to address unmet medical needs in areas such as ophthalmology, neurology, and rare diseases. The company is committed to advancing the field of gene therapy to improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

16 Patents

#43 in Rockville, MD

#276 in Maryland

#19,935 in US

#37,868 in the World

Rockville, MD, United States of America

Regenxbio Inc.

Forward Citations = 9

48 inventors:

Olivier Danos (5 out of 5 patents)

Ye Liu (4 out of 35 patents)

Devin Mcdougald (4 out of 4 patents)

4. Karen Kozarsky (3 out of 10 patents)

5. Franz M Gerner (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Regenxbio Inc.. Retrieved from https://idiyas.com/company/regenxbio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…